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Purpose: The treatments of nutraceuticals are currently used for
therapy in osteoarthritis. Clinical trials in human and veterinary
literature have documented the benefits of nutraceutical joint sup-
plements, such as glucosamine. However, there were not eluci-
dated significant histopathological and molecular changes in vivo
model. In this study, we investigated to evaluate the chondropro-
tective effects of glucosamine and/or mucopolysaccharide-pro-
tein comparing with treatment of COX-II inhibitor. Therefore we
observed degree of histopathological degradation and apoptosis
of articular cartilage in osteoarthritic rabbit model after adminis-
trations of glucosamine and/or mucopolysaccharide-protein.
Methods: Osteoarthritis was surgically induced in right knees
of rabbit by transecting the anterior cruciate ligament (ACLT).
Rabbits (six in each group) were received oral administration of
glucosamine-HCl (Glu) or mucopolysaccharide-protein (MucoP)
at a dose of 100 mg/kg, 6 times in a week. In the positive control
group, rabbits were treated COX-II inhibitor (celecoxib). Exper-
imental animals were examined by radiographs and sacrificed
at the 8th week of administration and removed the distal femora
for macroscopic and histological assessment. Apoptosis of chon-
drocytes were evaluated using TUNEL assay and immunohisto-
chemical expression of Caspase-3 in the cartilage area.
Results: In ACLT rabbits, there were not detected changes of
body weight due to administration of celecoxib, glucosamin-HCl
(Glu), or mucopolysaccharide-protein (MucoP) for 8 weeks. At
the 8-week after ACLT operation, radiographs of the right knees
varied from the lefts, but there were not significantly different be-
tween the groups. In gross morphology, critical osteoarthritic le-
sions, included fibrillation and irregularity of the cartilage surface,
were induced at the moderate and severe grade (as modifided
Mankin score). Histopathological quantitative evaluation of azan
stained sections in the medial femoral condyles were performed
and observed the severe loss of cartilage area and destruction
of tissue after ACLT. However, these gross and histopathological
lesions were significantly decreased in the rabbits of celecoxib
treatment. In particular, degenerative changes of cartilage and
cellularity of chondrocytes were reduced by oral treatment of Glu-
or MucoP- compared with those of non-treated rabbits. In MucoP-
treated rabbits, hypercellularity of chondrocytes was significantly
increased. In TUNEL assay of OA-induced rabbits, apoptosis of
chondrocytes frequently showed in surfaces of lateral and medial
femoral condyles. In the Glu- and celecoxib-treated groups, the
number of apoptotic chondrocytes was decreased. Moreover,
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Month 1 Month 3
Lumiracoxib dose Change relative to placebo 95% CI p Change relative to placebo 95% CI p
[mg/day] [mmHg] [mmHg]
Systolic BP
100 0.21 -0.75, 1.17 0.66 0.94 -0.32, 2.20 0.14
200 0.16 -0.68, 1.01 0.71 -0.32 -1.42, 0.79 0.57
400 0.37 -0.48, 1.23 0.39 0.16 -0.98, 1.31 0.78
Diastolic BP
100 0.16 -0.43, 0.75 0.59 0.46 -0.30, 1.22 0.24
200 0.03 -0.50, 0.56 0.91 -0.01 -0.69, 0.66 0.97
400 -0.11 -0.65, 0.42 0.68 -0.11 -0.81, 0.60 0.77
apoptosis of superficial zone was reduced in the cartilage of
MucoP-treated rabbits. In immunohistochemistry, the expression
of Caspase 3 was correlated with apoptotic changes between
groups.
Conclusions: In the ACLT rabbit model, osteoarthritis of ar-
ticular cartilage was significantly reduced by oral treatments
of glucosamin-HCl or mucopolysaccharide-protein for 8 weeks.
These data suggest that protective effects of nutraceuticals may
play a useful role in the clinical application. These effects could
be related to cartilage hypercellularity and reduction of apoptosis
due to treatment of glucosamine and/or mucopolysaccharide-
protein.
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Purpose: Hypertension is a leading co-morbidity in elderly arthri-
tis patients. Increases in systolic blood pressure (BP) of 1-5
mmHg have been shown to be associated with 7,100-35,700
additional ischemic heart disease and stroke events over 1 year
in a recent US study of osteoarthritis (OA) patients (Singh et
al. 2003). NSAIDs and COX-2 inhibitors have been shown to
increase BP, although there are differences among the individ-
ual drugs. Thus, chronic treatment of arthritis patients requires
selecting the most appropriate drug with a minimal impact on a
patient’s BP. In TARGET, lumiracoxib at a chronic dose of 400mg
od (four times the recommended dose for chronic osteoarthritis
used for up to one year) demonstrated a superior BP profile
than the comparator NSAIDs, ibuprofen 800mg tid and naproxen
500mg bid. To determine whether lumiracoxib increased blood
pressure compared to placebo-treated patients, we conducted a
meta-analysis of placebo-controlled trials including data of up to
3 months duration.
Methods: Office-visit, seated blood pressure measurement data
were available from 9,719 patients in 12 placebo-controlled trials
of up to 3 months duration. Change from baseline in diastolic and
systolic BP was examined for 6 different dose regimens of lumira-
coxib (50mg bid, 100mg od, 100mg bid, 200mg od, 200mg bid,
and 400mg od). Meta-analyses were conducted using individual
patient data from 9,611 patients providing BP measurements at
baseline and at least one post-baseline assessment. The effects
relative to placebo were evaluated at one and three months and
averaged across three months. Total daily doses of lumiracoxib
were used to investigate a dose-response relationship. The ef-
fects of baseline variables and prognostic factors on the relative
effect of lumiracoxib were also studied.
Results: Change from baseline for systolic and diastolic blood
pressure of lumiracoxib relative to placebo derived from a model
combining dose regimens (total daily dose) is shown in Table 1.
